[Phase 2] Standardized Diagnosis and Treatment Courses for Prostate Cancer——Strategies of Endocrine Therapy for Prostate Cancer

Explore the new world---standardized curriculum "Prostate Cancer Standardized Diagnosis and Treatment College" project is sponsored by the Beijing Medical Award Foundation, guided by the Chinese Anti-Cancer Association Urology and Andrology Reproductive Tumor Committee, and Yimaitong fully supports it.

Among them, the "Prostate Cancer Standardized Diagnosis and Treatment Course" aims to promote and promote the knowledge of standardized diagnosis and treatment of prostate cancer, and improve the academic level and professional skills in the field of prostate cancer across the country.

The second phase of "Prostate Cancer Standardized Diagnosis and Treatment Course" The second phase is "Strategies for Endocrine Therapy of Prostate Cancer" brought by Professor Dai Bo from Fudan University Affiliated Cancer Hospital: Click to watch the highlights video! Highlights Video Endocrine therapy has been used in the field of prostate cancer for many years, covering metastatic castration-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) ) And many different disease stages.

In recent years, with the development of new endocrine therapy drugs such as enzalutamide and other related research, the survival benefit of prostate cancer patients has been significantly improved, and the endocrine strategy of prostate cancer has also been greatly changed.

So, at the stage of mHSPC, nmCRPC and mCRPC, what are the new endocrine therapy drugs? How is the related research progress? This issue of "Strategies for Endocrine Therapy of Prostate Cancer" will discuss and share these topics in detail to help clinicians familiarize and master the progress of endocrine therapy in the field of prostate cancer and better apply new endocrine therapy drugs.

To watch the full video, please